These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 18165395

  • 1. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L, Gass M, Constantine G, Olivier S, Study 315 Investigators.
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [Abstract] [Full Text] [Related]

  • 2. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
    Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, Study 319 Investigators.
    Am J Obstet Gynecol; 2009 Mar; 200(3):238.e1-238.e10. PubMed ID: 19167693
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
    Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S.
    Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
    [Abstract] [Full Text] [Related]

  • 4. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P, Panay N, de Villiers TJ, Vincendon P, Bao W, Cheng RJ, Constantine G.
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [Abstract] [Full Text] [Related]

  • 5. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 6. Identifying meaningful differences in vasomotor symptoms among menopausal women.
    Wyrwich KW, Spratt DI, Gass M, Yu H, Bobula JD.
    Menopause; 2008 Jun; 15(4 Pt 1):698-705. PubMed ID: 18369313
    [Abstract] [Full Text] [Related]

  • 7. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
    Pinkerton JV, Constantine G, Hwang E, Cheng RF, Study 3353 Investigators.
    Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
    [Abstract] [Full Text] [Related]

  • 8. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA, Schaefers M, Uddin A, Utian WH.
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [Abstract] [Full Text] [Related]

  • 9. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ.
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [Abstract] [Full Text] [Related]

  • 10. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
    Pinkerton JV, Archer DF, Guico-Pabia CJ, Hwang E, Cheng RF.
    Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
    [Abstract] [Full Text] [Related]

  • 11. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.
    Cheng RJ, Dupont C, Archer DF, Bao W, Racketa J, Constantine G, Pickar JH.
    Climacteric; 2013 Feb; 16(1):17-27. PubMed ID: 22646219
    [Abstract] [Full Text] [Related]

  • 12. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women.
    Stevens RE, Hanford K, Wason S, Cusack SL, Phelps KV.
    Int J Fertil Womens Med; 2000 Feb; 45(4):264-72. PubMed ID: 10997482
    [Abstract] [Full Text] [Related]

  • 13. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG, Drosman S, Helmond FA, Stathopoulos VM.
    Menopause; 2006 Feb; 13(6):917-25. PubMed ID: 17006377
    [Abstract] [Full Text] [Related]

  • 14. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
    Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC.
    Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
    [Abstract] [Full Text] [Related]

  • 15. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
    Simon JA, ESTRASORB Study Group.
    Menopause; 2006 Mar; 13(2):222-31. PubMed ID: 16645536
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials.
    Sun Z, Hao Y, Zhang M.
    Gynecol Obstet Invest; 2013 Mar; 75(4):255-62. PubMed ID: 23548358
    [Abstract] [Full Text] [Related]

  • 17. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S, Walsh BW, Ciaccia AV, Siddhanti S, Rosen AS, Plouffe L.
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [Abstract] [Full Text] [Related]

  • 18. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.
    Gallagher JC, Strzinek RA, Cheng RF, Ausmanas MK, Astl D, Seljan P.
    J Womens Health (Larchmt); 2012 Feb; 21(2):188-98. PubMed ID: 22032759
    [Abstract] [Full Text] [Related]

  • 19. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ, Sun LZ, Lin JF, Yang X, Zhang LJ, Qiao J, Wang ZH, Xu YX, Xiong ZA, Lin SQ.
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [Abstract] [Full Text] [Related]

  • 20. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Garrido L, Bosio-Le Goux B, Saráchaga M, Graebe A, Niño AJ, Nickelsen T.
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.